Abstract
Bladder cancer is the 10th most common cancer and the 9th cause of death by malignancy worldwide. Invasiveness and morbidity of cystoscopy, relatively low sensitivity of urinary cytology, lack of clinically approved point of care devices specificity, and the cost of the existing diagnostic procedures have motivated scientists and technologists to develop new bladder cancer detection platforms. In the context of finding an efficient screening system, biosensors have the advantages of detecting the biomarkers of bladder cancer, high sensitivity, simple operation, and relatively low equipment cost. This review summarizes the pathophysiology, common treatments, and the most prominent bladder cancer biomarkers as well as the clinically approved point of care devices and the most recent biosensors and nanobiosensors for detection of bladder cancer biomarkers.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
